Search

Displaying results 3921 - 3930 of 10000 in total
  1. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773]

  2. Drug

    Avutometinib

    go.drugbank.com/drugs/DB15254
    ApprovedInvestigational

    [A273948] Avutometinib was approved by the US FDA in May 2025 in a co-package alongside [defactinib] (called Avmapki Fakzynja) for the treatment of recurrent KRAS-mutated low-grade serous ovarian cancer … Avutometinib is a small molecule kinase inhibitor targeted against RAF/MEK1, key regulators of the RAS/RAF/MEK/ERK (MAPK) pathway.

  3. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

    Mixtures: ZOLFO E POTASSIO CARBONATO NEW.FA.DEM., ZOLFO E POTASSIO CARBONATO NEW.FA.DEM.
  4. Drug

    Apis mellifera venom

    go.drugbank.com/drugs/DB10955
    Approved

    Apis mellifera venom is an extract of Apis mellifera venom. Apis mellifera venom is used in allergenic testing.

    Mixtures: ALUTARD SQ Bienengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml), ALUTARD SQ Bienengift Injektionssuspension (Anfangsbehandlung) (100 SQ E/ml, 1.000 SQ E/ml, 10.000 SQ E/ml und 100.000 SQ E/ml)Products: ALUTARD SQ Bienengift 100.000 SQ-E/ml Injektionssuspension (Fortsetzungsbehandlung)
  5. Drug

    Gedatolisib

    go.drugbank.com/drugs/DB11896
    ApprovedInvestigational

    Celcuity describes gedatolisib as the first FDA-approved therapy to inhibit the pathway comprehensively across all class I PI3K isoforms and both mTOR complexes. … [L63927] Its approval also addresses a population defined by the absence of a biomarker, as patients with PIK3CA wild-type disease were not eligible for the PI3Kα-selective options.

  6. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  7. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    Pipamperone is a typical antipsychotic of the _butyrophenone_ family used in the treatment of schizophrenia. … Synthesized in the year 1984, risperidone’s pharmacological properties were similar to pipamperone’s in that both block more serotonin more potently than dopamine [L1518].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Dopamine D2 Receptor Antagonists
  8. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

    Products: MEFEN DE 500 MG TABLETAS, MEFENAL TABLETAS DE 500 MG.
  9. Drug

    Turpentine

    go.drugbank.com/drugs/DB11120
    Approved

    Turpentine is composed of terpenes, mainly the monoterpenes alpha-pinene and beta-pinene with lesser amounts of carene, camphene, dipentene, and terpinolene.

  10. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.